Disruptive Thinking: What's Next for Pain

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Initiatives to reduce opioid prescription and opiod use are in force, but the need for effective pain relief, especially in areas like cancer, trauma and severe chronic pain, remains a pressing one.

How can the biopharma industry develop and support the development of new analgesic drugs and other alternative treatments to pain? This panel will include perspectives on critical clinical needs and perspectives on new avenues to novel non-addictive therapies as well as the capital, public policy and regulation needed to advance non-opioid pain options to market.
Director, Helping to End Addiction Long-term (HEAL) Initiative
National Institutes of Health
Principal Deputy Administrator for Policy & Operations
Centers for Medicaid & Medicare Services
President & Chief Executive Officer
Artelo Biosciences
Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.